Point72 Asset Management
AMLX icon

Point72 Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Point72 Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Buy
+8,200
New +$127K ﹤0.01% 3612

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Point72 Asset Management's AMLX Position: Q2 2026 in Review

Point72 Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 106,535 shares — an estimated $1.65M sold.

Point72 Asset Management first reported a position in AMLX in Q2 2022 and held it in 14 quarters. The position peaked at $78.6M in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Point72 Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 106,535 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Point72 Asset Management first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Point72 Asset Management's Amylyx Pharmaceuticals position peaked at $78.6M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.